NuMe Health Raises $1.5M in Series A Financing

NuMe Health, a New Orleans-based biotech startup developing products that modify the bacteria that live in the gastrointestinal tract, has raised $1.5m in Series A financing

The round was led by BVM, with participation of company insiders, and new private investors.

Led by Dean P. Stull, PhD, chief executive officer, NuMe is initiating a clinical trial of its lead cobiotic product, NM504, which is being developed for the prediabetic population to support maintenance of healthy blood glucose levels and metabolic fitness.
The company intends to use the funds to advance NM504 towards commercialization, including developing the initial format for its first consumer product, completing the pilot clinical trial and preparing for an initial direct-to-consumer launch.



Join the discussion